Lead CML researcher discusses the evolution of a groundbreaking treatment and its effect on patient survival. When imatinib (Gleevec; Novartis), the first-ever tyrosine kinase inhibitor, made its ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback